Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 833-847 , October 2007

Targeting the treatment of drug abuse with molecular imaging

Received 20 March 2007 ,Revised 30 April 2007 ,Accepted 12 May 2007.

References 

  1. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci. 1998;1:132–137
  2. Wood RW. Stimulus properties of inhaled substances. Environ Health Perspect. 1978;26:69–76
  3. Blokhina EA, Dravolina OA, Bespalov AY, Balster RL, Zvartau EE. Intravenous self-administration of abused solvents and anesthetics in mice. Eur J Pharmacol. 2004;485:211–218
  4. Gerasimov MR, Collier L, Ferrieri A, Alexoff D, Lee D, Gifford AN, et al. Toluene inhalation produces a conditioned place preference in rats. Eur J Pharmacol. 2003;477:45–52
  5. Lee DL, Gerasimov MR, Schiffer WK, Gifford AN. Concentration-dependent conditioned place preference to inhaled toluene vapors in rats. Drug Alcohol Depend. 2006;85:87–90
  6. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52:456–463
  7. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, et al. Relationship between psychostimulant-induced “high” and dopamine transporter occupancy. Proc Natl Acad Sci U S A. 1996;93:10388–10392
  8. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of “high”. J Pharmacol Exp Ther. 1999;288:14–20
  9. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325–1331
  10. Quinn DI, Wodak A, Day RO. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet. 1997;33:344–400
  11. Griffiths IR, Kelly PA, Carmichael S, McCulloch M, Waterston M. The relationship of glucose utilization and morphological change in the visual system in hexacarbon neuropathy. Brain Res. 1981;222:447–451
  12. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals — implications for problems of long-term use and abuse. Psychopharmacology. 1997;134:1–37
  13. Bowen SE, Wiley JL, Jones HE, Balster RL. Phencyclidine- and diazepam-like discriminative stimulus effects of inhalants in mice. Exp Clin Psychopharmacol. 1999;7:28–37
  14. Geller I, Hartmann RJ, Mendez V, Gause EM. Toluene inhalation and anxiolytic activity: possible synergism with diazepam. Pharmacol Biochem Behav. 1983;19:899–903
  15. Geller I, Hartmann RJ, Randle SR, Gause EM. Effects of acetone and toluene vapors on multiple schedule performance of rats. Pharmacol Biochem Behav. 1979;11:395–399
  16. Wood RW, Coleman JB, Schuler R, Cox C. Anticonvulsant and antipunishment effects of toluene. J Pharmacol Exp Ther. 1984;230:407–412
  17. Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV. Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology. 1991;103:154–161
  18. Volkow ND, Fowler JS, Wolf AP, Gillespi H. Metabolic studies of drugs of abuse. NIDA Res Monogr. 1991;105:47–53
  19. Gerasimov MR, Ferrieri RA, Pareto D, Logan J, Alexoff D, Ding YS. Synthesis and evaluation of inhaled [(11)C]butane and intravenously injected [(11)C]acetone as potential radiotracers for studying inhalant abuse. Nucl Med Biol. 2005;32:201–208
  20. Gerasimov MR. Brain uptake and biodistribution of [11C]toluene in nonhuman primates and mice. Methods Enzymol. 2004;385:334–349
  21. Gerasimov MR, Ferrieri RA, Schiffer WK, Logan J, Gatley SJ, Gifford AN, et al. Study of brain uptake and biodistribution of [11C]toluene in non-human primates and mice. Life Sci. 2002;70:2811–2828
  22. Muller RD, Ferrieri RA, Gerasimov M, Garza V. Supercritical CO2 fluid radiochromatography system used to purify [11C]toluene for PET. Nucl Med Biol. 2002;29:351–357
  23. Gospe SM, Calaban MJ. Central nervous system distribution of inhaled toluene. Fundam Appl Toxicol. 1988;11:540–545
  24. Black KJ, Koller JM, Snyder AZ, Perlmutter JS. Atlas template images for nonhuman primate neuroimaging: baboon and macaque. Methods Enzymol. 2004;385:91–102
  25. DiVincenzo GD, Yanno FJ, Astill BD. Exposure of man and dog to low concentrations of acetone vapor. Am Ind Hyg Assoc J. 1973;34:329–336
  26. Gatley SJ, Volkow ND, Gifford AN, Ding YS, Logan J, Wang GJ. Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine. Biochem Pharmacol. 1997;53:43–52
  27. Knox JW, Nelson JR. Permanent encephalopathy from toluene inhalation. N Engl J Med. 1966;275:1494–1496
  28. Grabski DA. Toluene sniffing producing cerebellar degeneration. Am J Psychiatry. 1961;118:461–462
  29. Rosenberg NL, Sharp CW. Solvent toxicity: a neurological focus. In:  Sharp CW,  Beauvais F,  Spence R editor. Inhalant abuse: a volatile research agenda. NIDA Res Monogr. Rockville (Md): National Institute of Drug Abuse; 1992;p. 117–127
  30. Funada M, Sato M, Makino Y, Wada K. Evaluation of rewarding effect of toluene by the conditioned place preference procedure in mice. Brain Res Brain Res Protoc. 2002;10:47–54
  31. Yavich L, Patkina N, Zvartau E. Experimental estimation of addictive potential of a mixture of organic solvents. Eur Neuropsychopharmacol. 1994;4:111–118
  32. Lee DE, Schiffer WK, Dewey SL. Gamma-vinyl GABA (vigabatrin) blocks the expression of toluene-induced conditioned place preference (CPP). Synapse. 2004;54:183–185
  33. Haggard HW. Studies on the absorption, distribution and elimination of acetone. J Ind Hyg Toxicol. 1944;26:133
  34. Bruckner JV, Peterson RG. Evaluation of toluene and acetone inhalant abuse: I. Pharmacology and pharmacodynamics. Toxicol Appl Pharmacol. 1981;61:27–38
  35. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci. 1992;654:171–191
  36. Di Chiara G, Imperato A. Drugs of abuse preferentially stimulate dopamine release in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274–5278
  37. Di Chiara G, Tanda G, Bassareo V, Pontieri F, Acquas E, Fenu S, et al. Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Ann N Y Acad Sci. 1999;877:461–485
  38. Fowler JS, Volkow ND. Multi-tracer PET studies of cocaine pharmacokinetics and pharmacodynamics. Med Chem Res. 1994;5:193–207
  39. Scheel-Kruger J. Dopamine–GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurol Scand Suppl. 1986;107:1–54
  40. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Gatley SJ, Dewey SS, et al. Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study. Am J Psychiatry. 1998;155:200–206
  41. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry. 1990;147:719–724
  42. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14:169–177
  43. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse. 1989;3:96–97
  44. Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 1993;13:350–356
  45. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CRJ. A pharmacologic strategy for the treatment of nicotine addiction. Synapse. 1999;31:76–86
  46. Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, et al. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab. 1997;17:932–942
  47. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology. 1998;18:18–25
  48. Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, et al. Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999;31:59–66
  49. Dewey SL, Smith GS, Logan J, Brodie JD, Yu DW, Ferrieri RA, et al. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci Res. 1992;12:3773–3780
  50. Ginovart N, Farde L, Halldin C, Swahn CG. Effect of reserpine-induced depletion of synaptic dopamine on [11C]raclopride binding to D2-dopamine receptors in the monkey brain. Synapse. 1997;25:321–325
  51. Hietala J, Kuoppamaki M, Nagren K, Lehikoinen P, Syvalahti E. Effects of lorazepam administration on striatal dopamine D2 receptor binding characteristics in man — a positron emission tomography study. Psychopharmacology. 1997;132:361–365
  52. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 1995;15:821–829
  53. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1988;242:715–723
  54. Gawin FH, Ellinwood EH. Cocaine and other stimulants. Actions, abuse, and treatment. N Engl J Med. 1988;318:1173–1182
  55. Johanson CE, Fischman MW. The pharmacology of cocaine related to its abuse. Pharmacol Rev. 1989;41:3–52
  56. Reith ME. Cocaine receptors on monoamine transporters and sodium channels. NIDA Res Monogr. 1988;88:23–43
  57. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, Macgregor RR, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989;4:371–377
  58. Volkow ND, Fowler JS, Logan J, Gatley SJ, Dewey SL, MacGregor RR, et al. Carbon-11–cocaine binding compared at subpharmacological and pharmacological doses: a PET study. J Nucl Med. 1995;36:1289–1297
  59. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219–1223
  60. Mullani NA, Volkow ND. Positron emission tomography instrumentation: a review and update. Am J Physiol Imaging. 1992;7:121–135
  61. Bai B, Li Q, Holdsworth CH, Asma E, Tai YC, Chatziioannou A, et al. Model-based normalization for iterative 3D PET image reconstruction. Phys Med Biol. 2002;47:2773–2784
  62. Verebey K, Gold MS. From coca leaves to crack: the effects of dose and routes of administration in abuse liability. Psychiatr Ann. 1988;18:513–520
  63. Volkow ND, Gatley SJ, Fowler JS, Logan J, Fischman M, Gifford AN, et al. Cocaine doses equivalent to those abused by humans occupy most of the dopamine transporters. Synapse. 1996;24:399–402
  64. Pettit HO, Justice JB. Effect of dose on cocaine self-administration behavior and dopamine levels in the nucleus accumbens. Brain Res. 1991;539:94–102
  65. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52:456–463
  66. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemannn R, Gatley SJ, et al. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology. 1996;14:159–168
  67. Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci. 1998;18:419–427
  68. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther. 1985;233:539–544
  69. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998;18:8417–8422
  70. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377–382
  71. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with pet. Am J Psychiatry. 2001;158:1206–1214
  72. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37:554–559
  73. Friedman SD, Castaneda E, Hodge GK. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav. 1998;61:35–44
  74. Cass WA, Manning MW. Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci. 1999;19:7653–7660
  75. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res. 1997;766:113–120
  76. Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R, et al. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry. 2004;161:242–248
  77. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414–9418
  78. Wise RA. Addiction becomes a brain disease. Neuron. 2000;26:27–33
  79. Domino EF. Brain imaging of nicotine and tobacco smoking. Ann Arbor (Mich): NPP Books; 1995;
  80. Clarke PB, Fu DS, Jakubovic A, Fibiger HC. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther. 1988;246:701–708
  81. Bergstrom M, Nordberg A, Lunell E, Antoni G, Langstrom B. Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther. 1995;57:309–317
  82. Stapleton JM, Henningfield JE, Wong DF, Phillips RL, Grayson RF, Dannals RF, et al. Nicotine reduces cerebral glucose utilization in humans. In: NIDA Res Monogr. Washington (DC): DHHS; 1993;p. 106
  83. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A. 1996;93:14065–14069
  84. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379:733–736
  85. Yu PH, Durden DA, Davis BA, Boulton AA. Interaction of biogenic amines with components of cigarette smoke. Formation of cyanomethylamine derivatives. Biochem Pharmacol. 1988;37:3729–3734
  86. Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther. 1995;58:444–452
  87. Caldecott-Hazard S, Schneider LS. Clinical and biochemical aspects of depressive disorders: III. Treatment and controversies. Synapse. 1992;10:141–168
  88. Newhouse PA, Hughes JR. The role of nicotine and nicotinic mechanisms in neuropsychiatric disease. Br J Addict. 1991;86:521–526
  89. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine–haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996;15:429–436
  90. Schiffer WK, Gerasimov MR, Marsteller DA, Geiger J, Barnett C, Alexoff DL, et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse. 2001;42:196–198
  91. Schiffer WK, Gerasimov MR, Bermel RA, Brodie JD, Dewey SL. Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study. Life Sci. 2000;66:PL169–PL173
  92. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47(Suppl 1):227–241
  93. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274–5278
  94. Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR. Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology. 2004;29:259–268
  95. Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF. Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. Synapse. 2002;45:207–212
  96. Cumming P, Rosa-Neto P, Watanabe H, Smith D, Bender D, Clarke PB, et al. Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. Neuroimage. 2003;19:1127–1136
  97. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry. 2004;161:1211–1218
  98. Brody AL, Mandelkern MA, Lee G, Smith E, Sadeghi M, Saxena S, et al. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res. 2004;130:269–281
  99. Pouletty P. Drug addictions: towards socially accepted and medically treatable diseases. Nat Rev Drug Discov. 2002;1:731–736
  100. O'Brien CP. A range of research-based pharmacotherapies for addiction. Science. 1997;278:66–70
  101. Dewey SL, Wolf AP, Fowler JS, Brodie JD, Shiue C-Y, Alavi A, et al. The effects of central cholinergic blockage on [18F]-N-methylspiroperidol binding in the human brain using PET. In: XVIth CINP Congress. 96:1988;p. 162
  102. Dewey SL, MacGregor RR, Brodie JD, Bendriem B, King PT, Volkow ND, et al. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. Synapse. 1990;5:213–223
  103. Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev. 1993;18:75–113
  104. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol. 1998;54:679–720
  105. Li Y, Hu XT, Berney TG, Vartanian AJ, Stine CD, Wolf ME, et al. Both glutamate receptor antagonists and prefrontal cortex lesions prevent induction of cocaine sensitization and associated neuroadaptations. Synapse. 1999;34:169–180
  106. Li Y, White FJ, Wolf ME. Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. Psychopharmacology. 2000;151:175–183
  107. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–1308
  108. Dewey SL, Chaurasia CS, Chen CE, Volkow ND, Clarkson FA, Porter SP, et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse. 1997;25:393–398
  109. Kushner SA, Dewey SL, Kornetsky C. Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology. 1997;133:383–388
  110. Morgan AE, Dewey SL. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse. 1998;28:60–65
  111. Dewey SL, Morgan AE, Ashby CR, Horan B, Kushner SA, Logan J, et al. A novel strategy for the treatment of cocaine addiction. Synapse. 1998;30:119–129
  112. Petroff OA, Rothman DL. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. Mol Neurobiol. 1998;16:97–121
  113. Swerdlow NR, Vaccarino FJ, Amalric M, Koob GF. The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings. pharmacology. Biochem Behav. 1986;25:233–248
  114. Jackson MF, Esplin B, Capek R. Reversal of the activity-dependent suppression of GABA-mediated inhibition in hippocampal slices from gamma-vinyl GABA (vigabatrin)-pretreated rats. Neuropharmacology. 2000;39:65–74
  115. Wu Y, Wang W, Richerson GB. GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter. J Neurosci. 2001;21:2630–2639
  116. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP, Dewey SL. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol Biochem Behav. 2001;68:291–299
  117. Bevins RA, Besheer J, Pickett KS. Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression. Pharmacol Biochem Behav. 2001;68:135–145
  118. Schiffer WK, Marsteller D, Dewey SL. Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology. 2003;168:339–343
  119. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 1977;29:797–802
  120. Gardner CR, Mallorga P, Klein J, Huot-Olivier S, Palfreyman MG. Chronic elevation of brain GABA by gamma-vinyl GABA treatment does not alter the sensitivity of GABAergic or dopaminergic receptors in rat CNS. Psychopharmacology. 1983;79:130–136
  121. Neal MJ, Shah MA. Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br J Pharmacol. 1990;100:324–328
  122. Roberts DC, Brebner K. GABA modulation of cocaine self-administration. Ann N Y Acad Sci. 2000;909:145–158
  123. Schiffer WK, Logan J, Dewey SL. Positron emission tomography studies of potential mechanisms underlying phencyclidine-induced alterations in striatal dopamine. Neuropsychopharmacology. 2003;28:2192–2198
  124. Kushner SA, Dewey SL, Kornetsky C. Comparison of the effects of vigabatrin on cocaine self-administration and food reinforcement. Soc Neurosci Abstr. 1997;23:1942
  125. Buckett WR. The influence of a GABA transaminase inhibitor, gamma-vinyl GABA, on voluntary morphine consumption in the rat. Psychopharmacology. 1981;75:214–216
  126. Paul M, Dewey SL, Gardner EL, Brodie JD, Ashby CR. Gamma-vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats. Synapse. 2001;41:219–220
  127. Brodie JD, Figueroa E, Dewey SL. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse. 2003;50:261–265
  128. Fechtner RD, Khouri AS, Figueroa E, Ramirez M, Federico M, Dewey SL, et al. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. Arch Ophthalmol. 2006;124:1257–1262
  129. Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55:122–125
  130. Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, et al. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000;295:1070–1076
  131. Weinstein A, Feldtkeller B, Malizia A, Wilson S, Bailey J, Nutt DJ. Integrating the cognitive and physiological aspects of craving. J Psychopharmacol. 1998;12:31–38
  132. Sadzot B, Mayberg HS, Frost JJ. Imaging opiate receptors in the human brain with positron emission tomography. Potential applications for drug addiction research. Acta Psychiatr Belg. 1990;90:9–19

PII: S0969-8051(07)00132-1

doi: 10.1016/j.nucmedbio.2007.05.004

Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 833-847 , October 2007

Article Tools

* Image Usage & Resolution